Albertsons Companies, Inc. (ACI) - 10-K Filing Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Albertsons Companies, Inc. for the fiscal year ended February 28, 2026 (Fiscal 2025). The fiscal year consisted of 53 weeks. Albertsons is one of the largest food and drug retailers in the United States, operating 2,244 stores across 35 states and the District of Columbia under 22 banners, including Albertsons, Safeway, and Jewel-Osco. The company employs approximately 280,000 associates and operates 1,713 in-store pharmacies.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Net Sales and Other Revenue | $83,172.5 million | $80,390.9 million |
| Gross Margin | $22,606.7 million (27.2%) | $22,255.6 million (27.7%) |
| Operating Income | $727.6 million | $1,546.1 million |
| Net Income (GAAP) | $217.4 million ($0.40 per share) | $958.6 million ($1.64 per share) |
| Adjusted Net Income | $1,209.3 million ($2.18 per share) | $1,382.4 million ($2.34 per share) |
| Adjusted EBITDA | $3,901.5 million | $4,004.7 million |
| Operating Cash Flow | $2,366.7 million | $2,680.6 million |
| Total Debt (including finance leases) | $8,946.6 million | $7,820.1 million |
| Cash and Cash Equivalents | $198.6 million | $293.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.5% to $83.2 billion, driven by a 2.0% increase in identical sales (excluding fuel) and the impact of the 53rd week. Digital sales grew 21% year-over-year.
- Profitability Decline: GAAP Net Income decreased significantly to $217.4 million from $958.6 million. This decline was primarily due to a $773.8 million pre-tax charge ($599.8 million net of tax) related to the Opioid Settlement Framework recorded in the fourth quarter.
- Margin Pressure: Gross margin rate decreased 50 basis points to 27.2%, attributed to strong growth in lower-margin pharmacy sales and increased delivery/handling costs from digital expansion.
- Debt Increase: Total debt increased by $1.1 billion to $8.9 billion. The company issued new senior unsecured notes to refinance maturing debt and fund an accelerated share repurchase (ASR) agreement.
- Store Count: The company closed 35 stores and opened 9 new stores, resulting in a net decrease of 26 stores to a total of 2,244.
Guidance, Outlook, and Risks
- Capital Allocation: The company repurchased $1.49 billion of common stock in Fiscal 2025, including a $750 million ASR. On April 14, 2026, the Board increased the quarterly dividend from $0.15 to $0.17 per share and authorized an additional $900 million in share repurchases, bringing the remaining authorization to $2.0 billion.
- Capital Expenditures: Fiscal 2025 CapEx was approximately $1.83 billion. The company expects Fiscal 2026 CapEx to range between $2.0 billion and $2.2 billion.
- Opioid Settlement: The company reached a settlement framework to resolve substantially all opioid-related claims. Payments of up to $655.1 million to states and $21.7 million to tribes are expected over nine years, with the first payment of $136.6 million due in April 2026.
- Key Risks:
- Regulatory & Legal: Ongoing litigation regarding the terminated merger with Kroger (seeking $600 million termination fee plus damages) and False Claims Act cases regarding pharmacy pricing.
- Operational: Labor negotiations with unions covering approximately 190,000 employees; 22,000 employees have contracts expiring in Fiscal 2026.
- Market: Intense competition, inflationary pressures on wages and commodities, and the impact of the Medicare Drug Negotiation Program on pharmacy margins.
Investor Verification Checklist
- Opioid Settlement Terms: Verify the final participation levels of states and tribes required to make the settlement framework effective and the specific timeline for the nine-year payment schedule.
- Kroger Merger Litigation: Monitor the status of the lawsuit against Kroger regarding the $600 million termination fee and the potential for additional damages, as well as the appeal of the State of Washington's attorney fee award.
- Labor Costs: Assess the outcome of upcoming collective bargaining agreements for the 22,000 employees with expiring contracts and the impact on wage rates and benefits.
- Pharmacy Margins: Evaluate the long-term impact of the Medicare Drug Negotiation Program (effective 2026) on pharmacy sales and profitability.
- Debt Covenants: Confirm compliance with the fixed charge coverage ratio covenant under the ABL Facility, which is triggered if excess availability falls below certain thresholds.